Interest in metabolic medicines is riding high, led by the popular class of weight management drugs known as GLP-1 agonists. BioAge Labs aims to help those medications work better with a lead drug ...

This discovery is based on a protein called "apelin". 1 This protein is not only a "key" that is different from insulin; it also passes through a different receptor or "doorway". In type II ...

The project builds on work at Cambridge to understand the role apelin receptors play in cardiovascular conditions including ischemic heart disease and discover a selective antagonist of the target.

While no financial details were disclosed, BioAge will conduct a phase 2 trial of its oral apelin receptor agonist BGE-105 (azelaprag) along with Lilly’s GLP-1/GIP receptor agonist tirzepatide ...